{"protocolSection": {"identificationModule": {"nctId": "NCT02698241", "orgStudyIdInfo": {"id": "INTERVENE-HF"}, "organization": {"fullName": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}, "briefTitle": "Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure", "officialTitle": "Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure"}, "statusModule": {"statusVerifiedDate": "2019-12", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-02-29", "studyFirstSubmitQcDate": "2016-02-29", "studyFirstPostDateStruct": {"date": "2016-03-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-09-30", "resultsFirstSubmitQcDate": "2019-11-13", "resultsFirstPostDateStruct": {"date": "2019-12-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-12-20", "lastUpdatePostDateStruct": {"date": "2019-12-30", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medtronic Cardiac Rhythm and Heart Failure", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true}, "descriptionModule": {"briefSummary": "The INTERVENE-HF study is a prospective, non-randomized, multi-center (US only), investigational, feasibility study. The purpose of this study is to characterize safety of managing heart failure patients with integrated device diagnostics that have an implanted commercially available Medtronic cardiac resynchronization therapy defibrillator (CRT-D).", "detailedDescription": "The study is expected to be conducted at up to 20 centers located in the United States. Up to 400 subjects will be enrolled to yield up to 200 eligible subjects that meet screening criteria. This study will be conducted in subjects with an implanted, commercially available, Medtronic, CRT-D device. Each enrolled subject will be followed every 2 months from time of enrollment to end of the study.The study will end after the last enrolled subject completes the 12-month follow-up."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Cardiac Resynchronization Therapy Defibrillator (CRT-D)", "heart failure", "integrated diagnostics", "chronic medication management"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 79, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Diagnostic & Medication Management", "type": "OTHER", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.", "interventionNames": ["Device: Diagnostic & Medication Management"]}], "interventions": [{"type": "DEVICE", "name": "Diagnostic & Medication Management", "description": "Single Arm Study. Subjects will be managed using integrated diagnostics.", "armGroupLabels": ["Diagnostic & Medication Management"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Effectiveness of the Integrated Diagnostic Medication Intervention Strategy (i.e. Percentage of Implemented Interventions Being Effective)", "description": "The Integrated Diagnostic Medication Intervention Strategy was physician-directed and nurse-implemented and it was based on a heart failure risk score diagnostic feature of a Medtronic CRT-D device implanted in the patients with heart failure. Effectiveness of this intervention strategy was measured as the percentage of implemented interventions being effective. Once initiated, an Integrated Diagnostic Medication Intervention would be effective if all the following criteria were met:\n\n1. The intrathoracic impedance of a subject recovered per defined criterion after completion of the Integrated Diagnostic Medication Intervention;\n2. The subject had no HF-related event (as adjudicated by the CEC) during or in the next 14 days after completion of the Integrated Diagnostic Medication Intervention;\n3. The subject had not experienced any adverse events that were related to the Integrated Diagnostic Medication Intervention per CEC adjudication and require medical care.", "timeFrame": "12 months post enrollment"}, {"measure": "Safety of the Integrated Diagnostic and Medication Management (i.e. Percentage of Implemented Interventions Being Safe)", "description": "The Integrated Diagnostic Medication Intervention Strategy was physician-directed and nurse-implemented and it was based on a heart failure risk score diagnostic feature of a Medtronic CRT-D device implanted in the patients with heart failure. Safety of this intervention strategy was measured as the percentage of implemented interventions being safe. Once initiated, the Integrated Diagnostic Medication Intervention Strategy would be regarded as being safe if all the following criteria were met:\n\n1. The Integrated Diagnostic Medication Intervention applied to an episode was not terminated due to safety issues;\n2. The Integrated Diagnostic Medication Intervention applied to an episode had not caused treatment-related adverse events (as adjudicated by the CEC).", "timeFrame": "12 months post enrollment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subject (or subject's legally authorized representative) is willing and able to provide written informed consent\n* Subject has been implanted with a CRT device for at least 9 months and has had a wireless Medtronic CRT-D device for at least 34 days\n* Subject has \\>1 year life expectancy\n* Subject's CRT-D device has at least 18 months of device longevity left\n* Subject has an eGFR\\> 25 ml/min/1.73 m2\n* Subject is NYHA Class II or III\n* Subject is NYHA Class II or III \u2022 Subject has elevated BNP values (BNP\\>400 or NTpro BNP\\>800) within the last 3 months OR Subject has had at least one OptiVol threshold crossing in the last 9 months OR Subject has had a HF event within the last 9 months\n\nHF event is defined as meeting any one of the following two criteria:\n\n1. Subject was admitted to the hospital for worsening HF OR\n2. Subject has received Intravenous HF therapy (e.g. IV diuretics/vasodilators) or ultrafiltration at any settings including:\n\n   * Emergency Department\n   * Ambulance\n   * Observation Unit\n   * Urgent Care\n   * HF/Cardiology Clinic\n   * Patient's Home\n\n     * Subjects who are currently prescribed and taking medications for the management of heart failure and are able to tolerate transient increases in diuretic dosage\n     * Subject is willing and able to comply with the protocol, including screening, baseline and programming visit(s), remote care directions, follow-up visits, and exit visit\n     * Subject can send device transmissions and daily biometric data with in-home patient devices\n\nExclusion Criteria\n\n* Subject has systolic BP of \\< 90 mmHg at the time of enrollment\n* Subject not responsive to diuretic therapy or is on chronic renal dialysis\n* Subject unable to undergo one round of medication intervention (3 day up-titration of diuretic) without requiring safety check\n* Subjects enrolled in a concurrent study that may confound the results of this study without documented pre-approval from a Medtronic study manager\n* Subject weighs more than 500 pounds\n* Subject is younger than 18 years of age\n* Subject has hemodynamic monitoring device implanted", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eduardo Warman, PhD", "affiliation": "Medtronic", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Phoenix Cardiovascular Research Group, LLC", "city": "Phoenix", "state": "Arizona", "zip": "85018", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Florida Heart Center", "city": "Fort Pierce", "state": "Florida", "zip": "34950", "country": "United States", "geoPoint": {"lat": 27.44671, "lon": -80.32561}}, {"facility": "Baptist Heart Specialists Research", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "First Coast Cardiology", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "South Miami Heart Specialists", "city": "Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Cardiology Partners", "city": "Wellington", "state": "Florida", "zip": "33449", "country": "United States", "geoPoint": {"lat": 26.65868, "lon": -80.24144}}, {"facility": "University of Mississippi Medical Center", "city": "Jackson", "state": "Mississippi", "zip": "39216", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "Lindner Research Center", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}]}, "referencesModule": {"references": [{"pmid": "33527654", "type": "DERIVED", "citation": "Zile MR, Costanzo MRR, Ippolito EM, Zhang Y, Stapleton R, Sadhu A, Jimenez J, Hobbs J, Sharma V, Warman EN, Streeter L, Butler J. INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2021 Apr;8(2):849-860. doi: 10.1002/ehf2.13231. Epub 2021 Feb 1."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A screening visit was required after a subject signed the informed consent form and before the baseline and programming visit. During the screening visit, subject's OptiVol Fluid Index and bloodwork were verified for the eligibility to continue the study. If subject failed the screening, he/she would exit the study.", "groups": [{"id": "FG000", "title": "Device Diagnostic & Diuretic and Chronic Medication Management", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan. This is a single arm feasibility study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Number of subjects enrolled the study", "numSubjects": "79"}]}, {"type": "Baseline & Programming", "comment": "Subject characteristics collected and device diagnostic enabled at baseline and programming visit.", "achievements": [{"groupId": "FG000", "comment": "Number of subjects that passed screening and completed baseline and programming visit", "numSubjects": "66"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Number of subjects completed the study (no early exit or death)", "numSubjects": "45"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}]}], "dropWithdraws": [{"type": "Inclusion/exclusion criteria not met", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Screening not met", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Subject underwent system modification", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Subject on inodrip not safe to continue", "reasons": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "geographic and licensing issue", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "After subjects passed the screening, they would attend the baseline \\& programming visit during which subjects' baseline characteristics was to be collected and OptiVol CareAlert should be turned on via device programming. Baseline analysis included subjects who passed the screening and completed the baseline \\& programming visit.", "groups": [{"id": "BG000", "title": "Device Diagnostic & Diuretic and Chronic Medication Management", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan. This is a single arm feasibility study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "66"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "72.9", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "46"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "57"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "66"}]}]}]}, {"title": "BMI", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.1", "spread": "6.4"}]}]}]}, {"title": "Systolic BP", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "119.6", "spread": "17.7"}]}]}]}, {"title": "Diastolic BP", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.6", "spread": "9.4"}]}]}]}, {"title": "NYHA Class", "description": "The New York Heart Association (NYHA) Functional Classification is commonly used to classify patients' heart failure according to the severity of their symptoms. It places patients in one of four categories based on how much they are limited during physical activity: Class I: No limitation of physical activity; Class II: Slight limitation of physical activity, comfortable at rest; Class III: Marked limitation of physical activity, comfortable at rest; Class IV: Unable to carry on any physical activity without discomfort. Higher classes mean worse conditions.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Class I", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Class II", "measurements": [{"groupId": "BG000", "value": "27"}]}, {"title": "Class III", "measurements": [{"groupId": "BG000", "value": "39"}]}, {"title": "Class IV", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Having heart failure events in previous 6 months", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "13"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "53"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Effectiveness of the Integrated Diagnostic Medication Intervention Strategy (i.e. Percentage of Implemented Interventions Being Effective)", "description": "The Integrated Diagnostic Medication Intervention Strategy was physician-directed and nurse-implemented and it was based on a heart failure risk score diagnostic feature of a Medtronic CRT-D device implanted in the patients with heart failure. Effectiveness of this intervention strategy was measured as the percentage of implemented interventions being effective. Once initiated, an Integrated Diagnostic Medication Intervention would be effective if all the following criteria were met:\n\n1. The intrathoracic impedance of a subject recovered per defined criterion after completion of the Integrated Diagnostic Medication Intervention;\n2. The subject had no HF-related event (as adjudicated by the CEC) during or in the next 14 days after completion of the Integrated Diagnostic Medication Intervention;\n3. The subject had not experienced any adverse events that were related to the Integrated Diagnostic Medication Intervention per CEC adjudication and require medical care.", "populationDescription": "All subjects who had received the Integrated Diagnostic Medication Intervention per protocol were in the scope of this endpoint analysis. The interest was the effectiveness of the implemented interventions.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of effective interventions", "timeFrame": "12 months post enrollment", "typeUnitsAnalyzed": "Interventions Implemented", "denomUnitsSelected": "Interventions Implemented", "groups": [{"id": "OG000", "title": "Device Diagnostic & Diuretic and Chronic Medication Management", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan. This is a single arm feasibility study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}, {"units": "Interventions Implemented", "counts": [{"groupId": "OG000", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "69.2"}]}]}]}, {"type": "PRIMARY", "title": "Safety of the Integrated Diagnostic and Medication Management (i.e. Percentage of Implemented Interventions Being Safe)", "description": "The Integrated Diagnostic Medication Intervention Strategy was physician-directed and nurse-implemented and it was based on a heart failure risk score diagnostic feature of a Medtronic CRT-D device implanted in the patients with heart failure. Safety of this intervention strategy was measured as the percentage of implemented interventions being safe. Once initiated, the Integrated Diagnostic Medication Intervention Strategy would be regarded as being safe if all the following criteria were met:\n\n1. The Integrated Diagnostic Medication Intervention applied to an episode was not terminated due to safety issues;\n2. The Integrated Diagnostic Medication Intervention applied to an episode had not caused treatment-related adverse events (as adjudicated by the CEC).", "populationDescription": "All subjects who had received the Integrated Diagnostic Medication Intervention per protocol were in the scope of this endpoint analysis. The interest was the safety of implemented interventions", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of safe interventions", "timeFrame": "12 months post enrollment", "typeUnitsAnalyzed": "Interventions Implemented", "denomUnitsSelected": "Interventions Implemented", "groups": [{"id": "OG000", "title": "Device Diagnostic & Diuretic and Chronic Medication Management", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan. This is a single arm feasibility study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}]}, {"units": "Interventions Implemented", "counts": [{"groupId": "OG000", "value": "26"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "In this study, adverse event data were collected from the time participants signed the informed consent to the time they died or completed the exit visit. The study planned to follow up subjects for 12 months.", "description": "Only the following adverse events were monitored/assessed: all system-related adverse events (AEs), all cardiovascular-related AEs, all AEs that might be associated with the PRN intervention, and all serious adverse events (SAEs).", "eventGroups": [{"id": "EG000", "title": "Device Diagnostic & Diuretic and Chronic Medication Management", "description": "Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan. This is a single arm feasibility study.", "deathsNumAffected": 2, "deathsNumAtRisk": 79, "seriousNumAffected": 34, "seriousNumAtRisk": 79, "otherNumAffected": 13, "otherNumAtRisk": 79}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 79}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 79}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Ischaemic hepatitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Clostridium difficile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Infective exacerbation of bronchiectasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 79}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Staphylococcal bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Staphylococcal sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Device battery issue", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Device lead damage", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 79}]}, {"term": "Breast mass", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 79}]}, {"term": "Diabetic foot", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Air embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Hypovolaemic shock", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 79}]}], "otherEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 79}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 21.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 79}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Enrollment was stopped after 79 patients were enrolled in the study and the preliminary safety interim data report was completed. The early stop was not due to any safety concerns. The sponsor deemed sufficient data had been collected."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Joe Hobbs Clinical Research Specialist", "organization": "Medtronic CRHF Clinical Research", "email": "joe.hobbs@medtronic.com", "phone": "800-633-8766"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-09-29", "uploadDate": "2019-09-30T16:00", "filename": "Prot_000.pdf", "size": 2038846}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2016-07-25", "uploadDate": "2019-09-30T16:02", "filename": "SAP_001.pdf", "size": 3526900}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M7411", "name": "Diuretics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}